Test Price
2,800 AED✅ Home Collection Available
CCDC103 Gene Primary Ciliary Dyskinesia (PCD Type 17) Genetic Test in UAE | 2800 AED | DHA Guidelines
Executive Summary & Core Metrics
- ✅ Diagnostic Accuracy: 99.9% sensitivity via next-generation sequencing (NGS), ISO 9001:2015 accredited.
- ✅ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM – 11 PM).
- ✅ Clinical Guidance: Post‑test tele‑consultation with a Consultant Medical Geneticist for result interpretation.
- ✅ Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The CCDC103 gene test uses next‑generation sequencing (NGS) on the Illumina NovaSeq™ platform to identify pathogenic variants causing primary ciliary dyskinesia type 17, an autosomal recessive disorder that impairs motile cilia function. This definitive molecular diagnosis replaces older electron‑microscopy biopsies and supports personalized management for chronic sinopulmonary disease, recurrent otitis, bronchiectasis, and situs inversus (Kartagener syndrome).
| Feature | Our CCDC103 NGS Test | Closest Alternative (Sanger / TEM Biopsy) |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity – full gene coverage including intron/exon boundaries | Limited to selected exons; may miss deep intronic or large deletions |
| Methodology | Illumina NovaSeq™ NGS with custom bioinformatics pipeline; validation against ClinVar & gnomAD | Single‑gene Sanger sequencing or ciliary ultrastructure analysis via TEM |
| Turnaround | 3‑4 weeks (expedited reporting available) | 6‑12 weeks for biopsy culture & EM; variable for Sanger |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I witness the profound impact of delayed primary ciliary dyskinesia diagnosis on respiratory health and quality of life. This NGS test illuminates the genetic root, enabling precise, multidisciplinary care and family counseling. Correlation with clinical imaging, ciliary beat studies, and family history remains essential — a genetic finding alone does not replace holistic evaluation. Never discontinue bronchodilators, inhaled corticosteroids, or antibiotics without consulting your pulmonologist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠ Medication Advisory
Do not discontinue prescribed medication without consulting your doctor. This test does not provide immediate treatment recommendations. Always adhere to your pulmonologist’s regimen.
Safety Exclusion Criteria
- Minor patients (<18 years) without legal guardian consent (per Federal Decree-Law No. 4 of 2016)
- Individuals with severe coagulopathy or active bleeding that contraindicates venipuncture
- Inability to provide informed consent or comply with pre‑test genetic counselling
Emergency Red Flags
If you experience sudden severe respiratory distress, hemoptysis, or pleuritic chest pain during the testing period, seek emergency medical care immediately. This genetic test is an outpatient diagnostic procedure and does not substitute acute medical intervention.
Patient FAQ & Clinical Guidance
1. Is a blood draw strictly necessary, or can I use a buccal swab?
Whole blood (3–5 mL in EDTA tube) is the standard. We also accept extracted DNA or a single drop of blood on an FTA card; buccal swabs are not validated due to lower DNA yield for NGS.
2. What does a “positive” result mean for my child’s health?
A positive CCDC103 result confirms the molecular basis of primary ciliary dyskinesia type 17, guiding lifelong respiratory care (chest physiotherapy, aggressive infection management) and informing reproductive options for the family.
3. Can I self‑register without a prescription?
You may self‑register, but a consultation with a Consultant Medical Geneticist is required for result interpretation and comprehensive genetic counselling, in compliance with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
UAE Regulatory & Data Privacy Adherence
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – genetic data treated as sensitive personal information, encrypted and stored within UAE borders.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governs secure handling of electronic health records.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – informed consent and adverse event reporting.
- Laboratory accredited to ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
- DHA Facility License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
For direct insurance billing verification, WhatsApp +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | CCDC103 Gene Primary Ciliary Dyskinesia (PCD Type 17) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks (expedited reporting available upon request) |
| Sample Type / Matrix | Whole blood (3–5 mL in EDTA tube), extracted DNA, or FTA card. VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina NovaSeq™; custom bioinformatics pipeline with ClinVar and gnomAD validation. |
| ICD-10-CM Code | Q89.9 (Congenital malformation, unspecified) / J98.9 (Other respiratory disorders) |
| LOINC Code | 82163-6 (Primary ciliary dyskinesia genetic testing panel) |
| DHA Facility License & Laboratory Address | License No. 1143 – DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians